Nanox Imaging Ltd. (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a sales reseller agreement with Vertec Scientific Ltd. to commercialize its AI bone solution, HealthOST, in the United Kingdom. Under the agreement, Vertec receives an exclusive license to market and resell HealthOST in the UK, with minimum annual license commitments, for an initial three-year term. This move underscores Nanox's strategy to broaden the adoption of its AI-driven diagnostic tools in key international markets.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes routine CT scans to support clinicians in evaluating musculoskeletal diseases of the spine, including osteoporosis. The software is designed to opportunistically detect vertebral fragility fractures, which are often underdiagnosed but can be early indicators of osteoporosis and increased fracture risk. By integrating into existing CT workflows, HealthOST aims to enhance diagnostic accuracy without requiring additional imaging or patient visits.
The significance of this agreement is amplified by the recent recommendation from the National Institute for Health and Care Excellence (NICE). In November 2025, NICE recommended HealthOST and its predecessor, HealthVCF, among five AI technologies for use in the National Health Service (NHS) to aid in the opportunistic detection of vertebral fragility fractures. This endorsement from NICE provides a strong foundation for Vertec's commercialization efforts, as NHS trusts may be more inclined to adopt a technology that has received national guidance.
The UK market presents a substantial opportunity for Nanox, given the NHS's emphasis on early detection and preventive care. Osteoporosis affects millions in the UK, and vertebral fractures are a common yet often missed sign of the condition. By leveraging AI to flag these fractures during routine CT scans, HealthOST could help identify at-risk patients earlier, enabling timely intervention and potentially reducing the burden of osteoporotic fractures on the healthcare system.
Vertec Scientific Ltd. is a well-established supplier of medical and scientific equipment in the UK, with a strong track record in distributing advanced diagnostic technologies. This partnership aligns with Vertec's portfolio and its commitment to bringing innovative solutions to the UK healthcare market. The exclusive arrangement ensures that Vertec will be the sole distributor of HealthOST in the UK, allowing for focused marketing and support efforts.
For Nanox, this agreement is part of a broader strategy to expand its global footprint and drive the adoption of its AI solutions. The company's ecosystem includes the Nanox.ARC digital tomosynthesis system, Nanox.AI suite, cloud-based platform, and teleradiology services, all aimed at improving access to medical imaging and early disease detection. By securing a foothold in the UK market, Nanox is positioning itself to capitalize on the growing demand for AI-powered diagnostic tools that enhance clinical efficiency and patient outcomes.
In addition to the commercial benefits, this partnership could have significant public health implications. Osteoporosis-related fractures are a major cause of morbidity and mortality, especially among the elderly. Early detection through opportunistic screening could lead to better management and prevention strategies, potentially reducing healthcare costs and improving quality of life for many individuals.
The three-year term of the agreement, with minimum annual commitments, suggests a long-term commitment from both parties. It also provides Vertec with the security needed to invest in marketing and educational initiatives to drive adoption among NHS trusts and private healthcare providers. The NICE recommendation is likely to be a key selling point, as it lends credibility and evidence-based support for the technology.
Nanox's focus on preventive healthcare aligns with global trends toward proactive management of chronic diseases. The use of AI to extract additional value from existing imaging data is a cost-effective approach that can be scaled across healthcare systems. As more countries recognize the benefits of such technologies, partnerships like this one may become increasingly common.
Overall, the exclusive UK reseller agreement for HealthOST is a strategic move that leverages NICE's endorsement to penetrate the NHS market. It highlights the potential of AI to improve osteoporosis detection and underscores Nanox's commitment to expanding access to innovative medical imaging solutions. The success of this partnership could pave the way for further international collaborations and broader adoption of AI in diagnostic imaging.
